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ABSTRACT  
 
Purpose: Studies on recovery from acute kidney injury (AKI) in ICU patients yield variable 
results. We assessed, in a heterogeneous ICU population, the impact of different recovery 
definitions, of different exclusion criteria and of imputing missing baseline creatinine on AKI 
recovery. 
 
Methods: Secondary analysis of the EPaNIC-database. Recovery of kidney function in patients 
who developed AKI in ICU was assessed at hospital discharge. We studied recovery rates of 
different AKI stages with different definitions of recovery after inclusion or exclusion of non-
survivors and in patients with or without chronic kidney disease (CKD). In addition, the impact 
of imputing missing baseline creatinine was investigated. 
 
Results: 1310 AKI patients were studied of which 977 were discharged alive from hospital. 
Rate of complete recovery (absence of KDIGO criteria) was markedly higher in survivors than 
in all AKI patients (79.5% vs 67.0%), especially for more severe forms of AKI. For patients 
with CKD, only the need for renal replacement therapy worsened kidney outcome as compared 
with no-CKD patients. Using stricter definitions of complete recovery significantly reduced its 
occurrence. New or worsening CKD occurred in 30% of AKI survivors. In no-CKD patients 
with available baseline creatinine, using an imputed baseline did not affect recovery. Patients 
with unavailable baseline creatinine were different from those with known baseline and 
revealed different recovery patterns.  
 
Conclusion: These results indicate the need for rigorous description of AKI severity, the 
included population, definitions and baseline creatinine handling in reports on AKI recovery. 
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Take home message: reports on recovery from AKI should clearly describe the applied 
definitions, AKI severity, the study population and the proportion of patients with imputed 
baseline.  
 
140-character tweet: recovery from AKI should clearly describe definitions, AKI severity, 
study population and proportion of patients with imputed baseline. 
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INTRODUCTION 
 
Several large observational studies have shown an association between acute kidney injury 
(AKI) and long-term mortality and the development of chronic kidney disease/end-stage renal 
disease (CKD/ESRD) [1,2]. Even a complete recovery from AKI has been suggested to 
predispose to long-term adverse outcomes [3-8], whereas absent or only partial recovery further 
aggravates this predisposition [4,9-12]. 
 
Most studies reporting short-term recovery from AKI used older definitions of AKI and/or 
focused on independence from dialysis in dialysis-requiring AKI [13,14]. Data on the renal 
outcome of AKI in ICU patients defined by modern definitions (RIFLE, AKIN, KDIGO) that 
also include less severe forms are scarce [13-26]. In addition, available studies are often small 
and limited to specific surgical populations [19-21,26,27], used only administrative or 
laboratory databases [10,11,25] or also included non-ICU patients [10,11,15,17,22,24,25].  
 
Evaluation of AKI recovery is hampered by the lack of a generally accepted definition. The 
available reports used definitions based on absence of RIFLE criteria [4,17,24], return to 
baseline serum creatinine (Screat) [11,19,27] or a discharge Screat that returned to a value 
below 1.1 or 1.25 times baseline [7,10,16,20]. Few studies reported recovery according to AKI 
severity [4,11,15] and none of these studies used the KDIGO criteria [28] for both diagnosis of 
AKI and for assessment of recovery. Using new-onset CKD or worsening of pre-existing CKD 
to define absence of recovery may be more clinically relevant in determining the need for 
nephrological follow-up [29].  
 
The optimal timing to evaluate recovery is also unclear. The majority of the available studies 
reported recovery at hospital discharge [17,19-25]. With the exception of studies focusing on 
long-term follow-up [4,5,10], recovery is mostly reported for all AKI patients (survivors and 
non-survivors) [15,16,18,19,21-23,26]. Although inclusion of non-survivors is important from 
a pathophysiological point of view and essential for intervention trials, recovery of kidney 
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function among survivors is probably more relevant from a patient’s perspective and crucial for 
determining the burden of postdischarge nephrological follow-up.  In- or excluding non-
survivors is expected to have a pronounced effect on the degree of renal recovery, especially in 
the most severe forms of AKI with the highest risk of death.  
 
Another complicating factor in determining AKI recovery is the fact that a baseline Screat is 
often missing. The available clinical trials either excluded patients with an unknown baseline 
Screat [9,19], used an imputed baseline Screat based on the Modification of Diet in Renal 
Disease (MDRD) equation (as suggested by ADQI and KDIGO) [4,16,17,23,25], used the 
minimum Screat measured during hospitalization [5,21] or did not mention how baseline Screat 
was determined [18,24]. The impact of using an imputed instead of the observed baseline on 
the incidence of AKI has been reported [30-32]. However, the impact of baseline Screat 
imputation on AKI recovery has not been studied. 
 
The aim of the current investigation was to compare the rate of complete, partial or absent 
recovery from different stages of AKI, defined by KDIGO criteria, in a large heterogeneous 
ICU population using different definitions of renal recovery, with in- and exclusion of non-
survivors and for patients with pre-existing CKD versus those without CKD. Our second aim 
was to assess the impact of using an imputed versus the true baseline Screat on the pattern of 
renal recovery. 
 
 
METHODS 
 
Patients 
This is a secondary analysis of the EPaNIC database [33]. EPaNIC was a prospective 
multicenter RCT of 4640 adult ICU patients who, between August 2007 and November 2010, 
were randomly assigned to early or late addition of parenteral nutrition to insufficient enteral 
nutrition. Written informed consent was obtained from all patients or their designated 
representatives. The institutional review board of the University Hospitals Leuven and the 
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Belgian authorities approved the protocol. For the present analysis patients were excluded if 
they were on chronic dialysis, were admitted after kidney transplantation or had incomplete 
data on kidney function during ICU stay. Baseline characteristics, including demographics, 
comorbidities and clinical parameters of illness severity were recorded. Daily clinical and 
biochemical data were entered in the study database. 
 
Definition of AKI  
AKI was classified according to the KDIGO criteria [28], however not taking into account the 
urine output. The “0.3mg/dL increase of Screat over 48h” criterion was only applied during 
ICU stay. As baseline Screat, we used the lowest Screat during the 3 months prior to ICU 
admission for elective admissions and the lowest Screat from 3 months to 1 week before ICU 
admission for emergency admissions. Screat was searched from the hospital database or 
manually retrieved by searching documents from referring hospitals/physicians.  In case of 
missing values a baseline Screat was imputed from the MDRD formula assuming an estimated 
GFR of 75ml/min per 1.73m2 [29]. The maximal AKI stage (AKImax) during ICU stay was 
recorded.  
 
Impact of the definition used to identify renal recovery at hospital discharge 
Definitions using serum creatinine criteria  
The first definition of recovery was based on the presence or absence of KDIGO criteria taking 
into account dialysis dependence and the percentage change of Screat compared with baseline. 
For patients with AKI stage 1 we separately evaluated the cohorts with 0.3mg/dL increase of 
Screat in 48h only and no other AKI criteria (further referred to as stage 1-0.3) and the cohort 
with 50% increase (further referred to as stage 1-50%). For patients with stage 3 we separated 
the 3-fold increase of serum creatinine and the need for renal replacement therapy (RRT) 
subcategories. Complete recovery from AKI was defined as being discharged from hospital 
without AKI (Screat below 1.5 times the baseline value). A reduction in AKI stage compared 
with AKImax was defined as partial recovery. Because of the important impact of dialysis need 
on health status patients with AKI stage 3 with need for RRT that did not need dialysis at 
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hospital discharge but still had AKI were also considered as partial recovery, even if they 
remained in stage 3. Absence of recovery was defined as persistent AKImax (persistent need for 
RRT for stage 3 with RRT) or worsening of AKI stage after ICU discharge. Besides the KDIGO 
criteria we also assessed 2 stricter definitions defining complete recovery as a return to below 
1.25 times baseline Screat or as a complete return to baseline Screat (without dialysis need). 
 
Definition using eGFR criteria 
This definition of recovery was based on the eGFR (MDRD equation) at hospital discharge in 
AKI survivors. Patients with discharge eGFR<60ml/min/1.73m2 were considered as potential 
CKD, since CKD strictu sensu requires a GFR below 60ml/min/1.73m2 for at least 3 months. 
We also determined the proportion of “new potential CKD” in patients without pre-existing 
CKD and the worsening of pre-existing CKD using the KDOQI classification [34]. 
 
Impact of the study population regarding survival status and pre-existing CKD 
The renal recovery pattern of different stages of AKImax in all AKI patients was compared with 
the subgroup of hospital survivors only. In addition, patients with pre-existing CKD were 
compared with those without CKD. 
 
Impact of imputation for missing baseline serum creatinine values 
For this analysis we excluded patients with stage 1-0.3 because this stage does not use a 
premorbid baseline creatinine. In AKI patients who survived to hospital-discharge and for 
whom baseline Screat was available, we compared the pattern of recovery with the true or 
calculated baseline: the “true baseline group” comprised the patients where both development 
and recovery of AKI was assessed with the true baseline and the “calculated baseline group” 
comprised the patients where both development and recovery of AKI was assessed with the 
calculated baseline. This analysis was performed in all AKI survivors and in the subgroup 
without pre-existing CKD. The “imputed baseline group” comprised the patients where the 
baseline was actually missing and had to be calculated. Their baseline characteristics and 
pattern of recovery were compared with the “calculated baseline group” without CKD.  
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Statistical analyses 
Continuous variables are expressed as medians and interquartile ranges (IQR) and compared 
with Wilcoxon or Kruskal-Wallis tests as appropriate. Categorical variables are expressed as 
frequencies and proportions and compared using the Chi-Square test or Fisher’s exact test. 
Agreement between two methods to evaluate recovery in the same population was assessed 
with kappa statistics and the Bowker’s test of symmetry. Statistical analysis was performed 
using JMP 10 software (SAS Institute, cary, NC) and a two-tailed p-value <0.05 was considered 
statistically significant, without correction for multiple testing. 
 
 
RESULTS 
 
Patients 
The EPaNIC study [33] included 4640 patients. The nutritional strategy itself had no significant 
impact on recovery from AKI [35]. From the original study population, 56 patients were 
excluded for ESRD, 15 for kidney transplantation and 9 for missing data required for this study. 
AKI was diagnosed in 1310/4560 patients (28.7%). Hundred and sixty patients (12.2%) had 
stage 1-0.3 and 425 (32.4%) had stage 1-50%; 213 (16.3%) had stage 2; 164 (12.5%) had stage 
3 without need for RRT and 348 (26.6%) needed RRT. Baseline characteristics and outcomes 
are described in Table 1 of the electronic supplement. Baseline Screat was unavailable in 31% 
of these AKI patients and this increased from 21% in patients with AKI stage 1 to 43% in 
patients with AKI stage 3. Pre-existing CKD was present in 24%. Mortality, ICU and hospital 
stay increased with increasing AKI severity.  
 
Impact of the definition and the study population 
Kidney outcome with KDIGO definition in the whole population versus survivors only 
Discharge KDIGO classification for the different levels of AKImax is shown in table 1, for all 
AKI patients and for survivors only. Survivors had 79.4% complete recovery, 10.8% partial 
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recovery and 9.8% absent recovery whereas these proportions were 30.6%, 12.3% and 57.1% 
for the non-survivors (p<0.0001). Death or no recovery occurred in 429 (32.7%). In comparison 
with the survivors the whole population had less complete recovery (67%) and more absent 
recovery (21.8%). This difference was most pronounced for the more severe AKI stages (Fig 
1). In AKI stage 3 with need for RRT, complete recovery was 60% in survivors and 37% in the 
total population. The characteristics of non-surviving patients and of survivors with complete, 
partial and absent recovery are shown in Table 2 of the electronic supplement. Important 
differences between the recovery groups existed with regard to baseline kidney function, 
emergency admission, Apache II score and AKI severity. 
 
Kidney outcome according to AKI severity 
As expected, complete recovery among survivors decreased substantially with increasing AKI 
severity (from 97.2% in stage 1-0.3 to 59.7% in stage 3 with RRT) (p<0.0001). In patients with 
AKI stage 3, the recovery pattern also significantly differed between the subgroups with and 
without need for RRT (p<0.0001) (Fig 1).  
 
Kidney outcome with KDIGO versus stricter definitions 
Defining complete recovery as a complete return to baseline Screat or as a return to below 1.25 
times the baseline Screat reduced the proportion of complete recovery in survivors from 79.4% 
to 42%, respectively 66%, with a parallel increase of partial recovery (p<0.0001) (Table 2).  
 
Kidney outcome in patients with versus without CKD 
Pre-existing CKD was present in 320 patients, of whom 81 (25.3%) died. Surviving patients 
with pre-existing CKD appeared to have a better renal outcome than those without CKD with 
the exception of patients requiring RRT (Fig 1 electronic supplement).   
 
Kidney outcome with eGFR definition (new or worsening CKD) 
Amongst the 977 AKI survivors, 420 (43%) had potential CKD at hospital discharge, the largest 
proportion being seen in stage 3 with need for RRT (Table 2). New or worsening CKD was 
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seen in 290 (29.6%) survivors, including new potential CKD in 230 (31%) of the 738 patients 
without pre-existing CKD and worsening CKD in 60 (25%) of the 239 AKI survivors with pre-
existing CKD.  Somewhat surprising, 49 (20%) of the CKD patients had an eGFR above 60 at 
hospital discharge. These patients had a higher baseline eGFR (50.8 (43-56.7) versus 39.4 
(30.6-48.6); p<0.0001) and a longer hospital stay compared with those with persistent CKD (29 
(21-56) versus 22 (15-38); p0.011).  
 
Impact of using imputation for missing baseline serum creatinine 
Comparing recovery in the “true baseline group” (n=577) with he “calculated baseline group” 
(n=725) (Fig 2A and Table 3 electronic supplement) showed less complete recovery with the 
calculated baseline (59.6% vs 80.4%; p=<0.0001). However, repeating the same analysis in the 
subgroup of patients without CKD (n=411/291) showed no difference in recovery pattern (p 
0.3). Compared with the “calculated baseline group” without CKD the “imputed baseline 
group” (n=258) had worse recovery (p<0.0001) (Fig 2B and Table 3 electronic supplement). 
Even after correction for AKI severity, the unavailability of a true baseline remained associated 
with less complete recovery (OR 0.69 (0.47-0.97). Comparing baseline characteristics of 
survivors with available and unavailable baseline showed significant differences. The 
“obligatory imputed patients” had less comorbidity, more emergency admissions, more sepsis 
on admission, higher illness severity, more AKI on admission and more severe AKI. They also 
had a longer ICU and hospital stay (Table 4).  
 
 
 
DISCUSSION 
 
This analysis describing renal recovery from AKI in a heterogeneous ICU population, showed 
that the pattern of recovery from AKI depends on the study population and on the definitions 
applied. AKI recovery, especially from the most severe forms, was markedly better when only 
survivors are considered. Pre-existing CKD only worsened renal outcome in stage 3 with need 
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for RRT. Not unexpectedly, recovery decreased with increasing AKI severity, with worst 
kidney outcome for the subgroup of AKI stage 3 with the need for RRT. The use of a more 
strict definition of recovery substantially reduced the proportion of complete recovery at the 
expense of more partial recovery. New or worsening CKD was present in 30% of the patients. 
Using a calculated versus a true baseline Screat in patients with available baseline did not affect 
recovery in patients without pre-existing CKD. However, patients with unavailable and thus 
obligatory imputed baseline creatinine had different baseline characteristics and a different 
recovery pattern when compared with those with available baseline Screat. These results plead 
for a clear description of the included population (in- or exclusion of non-survivors, proportion 
of CKD, AKI severity, method used for baseline creatinine assessment and proportion of 
patients with imputed baseline) in studies on this topic. 
 
Although one could argue that kidney outcome should be assessed in all AKI patients, the 
inclusion of non-survivors (as in [16,18,19,22-24,26]) not only induces bias (as patients may 
not have had enough time to recover before they died) but being dead with recovered kidneys 
also has little significance from a patient’s perspective. Since mortality increases with 
increasing AKI severity exclusion of non-survivors mainly affects the recovery pattern of more 
severe forms of AKI. Worsening renal recovery with increasing severity of AKI confirms 
previous findings [4,11,15,19,20] and underscores the importance of clearly reporting AKI 
severity, including the need for RRT in stage 3.  
 
The proportion of CKD patients included in the available studies on AKI recovery varies widely 
between 5% and 39% [16,20-23,25,26]. Renal outcome of AKI patients with preexisting CKD 
has been reported to be worse [15,19,20,36], similar [11,22] or better [10] than in no-CKD 
patients. In our cohort the presence of CKD appeared to result in a better renal outcome for the 
less severe AKI forms. This may potentially be explained by selection bias, as comorbidity 
determines the indication for postoperative ICU admission. CKD patients indeed had more 
elective admissions, a lower APII score and a shorter hospital stay (data not shown). However, 
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in those patients requiring RRT, the presence of CKD adversely affected recovery, as has been 
described previously [14,20,36].  
 
An ideal definition of recovery from AKI would compare baseline, minimal and final kidney 
function with a golden standard for GFR measurement such as inulin clearance. Since this is 
impossible in clinical practice clinicians will have to rely on the parameters that are available 
i.e. serum creatinine and the derived eGFR and AKI staging. Serum creatinine is not an ideal 
parameter to assess kidney outcome in ICU patients that frequently develop muscle wasting. 
Indeed, others and we have previously shown decreases in serum creatinine during ICU stay in 
patients without AKI [37,38]. Also in this analysis, 40% of the AKI survivors with true baseline 
(n=673) had a discharge creatinine lower than baseline (data not shown), suggesting that 
recovery may have been overestimated. 
 
We primarily defined recovery of AKI as the absence of AKI by the same criteria that are used 
for its diagnosis. Defining recovery from a disease as absence of this disease seems the most 
logical approach. Many studies used more strict definitions [7,10,16,19,20,22,24], which, as we 
have shown, only caused a shift from complete to partial recovery. Whether the difference in 
complete recovery between KDIGO and more strict definitions has implications for long-term 
outcome remains to be investigated.  
 
The most meaningful outcome from a patient’s perspective and for determining the need for 
nephrological follow-up is the presence of new or worsening CKD, which predominantly 
occurs in the most severe stages of AKI. We recognize that eGFR at hospital discharge may not 
be an ideal method to estimate recovery. Indeed, we have previously shown that eGFR in 
comparison with 24h creatinine clearance overestimates recovery at ICU discharge as a result 
of muscle wasting resulting in a reduced creatinine generation, especially in patients with 
prolonged ICU stay [37]. This phenomenon may also explain the 20% of the CKD patients who 
were “healed” from their CKD after an episode of AKI. Compared with those with persistent 
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CKD, these patients indeed had longer hospital stays and a baseline eGFR closer to the 
60ml/min/1.73m2 limit. 
 
Which of the evaluated definitions should be recommended in clinical practice depends on the 
context and purpose. For determining the need for nephrological follow-up and from a patient’s 
perspective the CKD status in survivors is likely the most meaningful, whereas in an 
intervention trial targeted at renal recovery, recovery has to be defined in comparison with 
baseline kidney function and assessed in the whole population, taking into account the 
competing end-point of mortality. Whether the absence of AKI criteria or stricter definitions of 
recovery are more appropriate requires further investigation on the relationship of these 
definitions of recovery with long-term patient and kidney outcome. 
 
Imputation of baseline Screat in patients with unavailable baseline is proposed by both ADQI 
and KDIGO [28] and was actually used in several clinical trials on AKI recovery 
[4,16,17,23,25]. We noted that patients with unknown baseline Screat had less complete 
recovery when compared with those with available baseline. This may be explained by the 
assumptions about the normality of kidney function prior to ICU admission that underlies this 
strategy and may thus result in underestimation of recovery in patients with “hidden” CKD. In 
addition, patients with unknown baseline showed different baseline characteristics, which may 
also explain their different recovery pattern. Exclusion of patients with unavailable baseline 
may therefore induce ascertainment bias. The proportion of patients with imputed baseline 
creatinine should be clearly reported, especially since the need for imputation was higher in the 
most severe forms of AKI.  
 
Strengths of this study are the large sample size, the use of a consensus definition for AKI 
diagnosis and active searching for baseline Screat, being available in the majority of the 
included patients, despite the high proportion of emergency admissions. On the other hand, this 
study also has limitations. We did not use the urine output criteria because these data were not 
available. It is possible that patients with both creatinine and urine output criteria or those 
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reaching a higher AKI severity due to oliguria criteria may have different recovery patterns. 
This will require further investigation. A recent analysis showed that patients reaching stage 3 
by both urine output and creatinine criteria have worse short- and long-term survival and 
dialysis need than those with either creatinine or oliguria alone [39]. The patient population was 
mainly surgical (79% of AKI patients). However, more than 40% had sepsis on admission and 
less than 50% were elective postoperative admissions, suggesting that the majority of the 
surgical patients were admitted after emergency surgery or after postoperative complications 
had developed (“medical patients with a scarf”). We did not use a fixed time point to assess 
recovery. Hospital discharge might be a too early time point to assess AKI recovery for two 
reasons: there is not enough time for recovery or patients may have developed muscle wasting 
resulting in decreased creatinine generation and thus overestimation of AKI recovery [37,38]. 
Restoration of muscle mass with rehabilitation after hospital discharge may then result in an 
apparent deterioration of kidney function. This phenomenon may also result in overestimation 
of recovery when the minimum Screat during hospitalization is used as a surrogate for baseline 
Screat. On the other hand, most reports on AKI recovery have reported kidney outcome at 
hospital discharge [17,19-25].  
 
Reliable data on AKI recovery have significant implications for planning nephrological follow-
up [40-42], for comparative research and for power calculations in future intervention studies. 
Our analysis suggests that, in order to be comparable, reports on recovery from AKI should 
provide detailed data on the included population (in-or exclusion of non-survivors, proportion 
of CKD), on the definition and severity of AKI, on the definition used for and the timing of 
recovery assessment and on the handling of missing baseline creatinine. 
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Fig legends 
 
Fig 1. Proportion of complete, partial and absent recovery for the total AKI group and split by 
different stages of AKImax in all AKI patients (blue) (n=1310) and in hospital survivors only 
(green) (n=997). 
 
Fig 2. A. Recovery in the “true baseline group” (n=577) (blue bars)  and the “calculated baseline 
group (n=725) (green bars) -  B. Recovery in no CKD patients in the “true baseline group 
(n=411) (blue bars) , the calculated baseline group (n= 291) (green bars) and in the “imputed 
baseline group (n=258) (gray bars) (see text for explanation of group composition) 
 
 
Fig 1 electronic supplement. Proportion of complete, partial and absent recovery for all patients 
and subgroups with different stages of AKImax in suvivors with available baseline without CKD 
(blue) (n=452) and with CKD (green) (n=239).  
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Table 1. Kidney outcome of different AKImax stages (absent recovery shown in dark gray, partial recovery in light gray) - A.in the total 
population  - B. in survivors only  
 
 A.         AKI discharge  No AKI Stage 1 Stage 2 
Stage 3  
no RRT 
Stage 3  
RRT 
AKI max Frequency- n (%)      
Stage 1   0,3 160 (12.2) 154 (96.2) 6 (3.8)    
Stage 1   50% 425 (34.4) 358 (84.2) 54 (12.7) 9 (2.1) 4 (0.9)  
Stage 2 213 (16.3) 151 (70.9) 40 (18.8) 20 (9.4) 2 (0.9)  
Stage 3  no RRT 164 (12.5) 87 (53) 24 (14.6) 31 18.9) 21 (12.8) 1 (0.6) 
Stage 3 RRT 348 (26.6) 128 (36.8) 27 (7.8) 18 (5.2) 6 (1.7) 169 (48.6) 
 1310 878 (67) 151 (11.5) 78 (6) 33 (2.5) 170 (13) 
 
 
  B.        AKI discharge  No AKI Stage 1 Stage 2 
Stage 3  
no RRT 
Stage 3  
RRT 
AKI max Frequency - n (%)      
Stage 1   0,3 142 (14.5) 138 (97.2) 4 (2.8)    
Stage 1   50% 372 (38) 320 (86) 44 (11.8) 7 (1.9) 1 (0.3)  
Stage 2 169 (17.3) 136 (80.5) 25 (14.8) 7 (4.1) 1 (0.6)  
Stage 3  no RRT 113 (11.6) 74 (65.5) 20 (17.7) 16 (14.2) 2 (1.8) 1 (0.9) 
Stage 3 RRT 181 (18.5) 108 (59.6) 24 (13.3) 17 (9.4) 3 (1.7) 29 (16) 
 977 776 (79.4) 117 (12) 47 (4.8) 7 (0.7) 30 (3.1) 
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Table 2. Frequency of complete recovery (n-%) in AKI survivors assessed with different definitions (* comparison with 
KDIGO) 
 
 All AKI P value* 
Bowker’s 
test 
Kappa (CI)* Stage 1 
0,3 
Stage 1 
50% 
Stage 2 Stage 3  
no RRT 
Stage 3  
RRT 
KDIGO 776 (79.4)   138 (97.2) 320 (86) 136 (80.5) 74 (65.5) 108 (59.7) 
Within 1,25 times 
baseline 
646 (66.1) <0.0001 0.67 (0.62-0.72) 133 (93.6) 262 (70.4) 104 (61.5) 60 (53.1) 87 (48.1) 
Return to baseline 410 (42) <0.0001 0.45 (0.41-0.50) 95 (66.9) 145 (39) 72 (42.6) 43 (38) 55 (30.4) 
Absence of new or 
worsening CKD 
687 (70.3) <0.0001 0.58 (0.52-0.64) 12 (8.4) 87 (23.4) 48 (28.4) 50 (44.2) 93 (51.4) 
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Table 3. Kidney outcome of different AKI stages (with the exception of stage 1 0,3) in surviving patients  - A. patients with 
available baseline and without CKD and development and recovery assessed with the true baseline (n=411) B. patients with 
available baseline and without CKD and development and recovery assessed with the imputed baseline (n=291) - C. patients 
with both development and recovery assessed with imputed baseline (n=258) (p-values for the distribution between complete, 
partial and no recovery are reported in Fig 3B)  
  A.      AKI disch  No AKI Stage 1 Stage 2 
Stage 3  
no RRT 
Stage 3  
RRT 
AKI max Frequency  - n (%)      
Stage 1   50% 231(56.2) 193 (83.5) 31 (13.4) 6 (2.6) 1 (0.4)  
Stage 2 93 (22.6) 74 (79.6) 15 (16.1) 3 (3.2) 1 (1.1)  
Stage 3  no RRT 41 (10) 31 (75.6) 8 (19.5) 1 (2.4) 1 (2.4)  
Stage 3 RRT 46 (11.2) 30 (65.2) 6 (13) 6 (13) 2 (4.3) 2 (4.3) 
 411 328 (79.8) 60 (14.6) 16 (3.9) 5 (1.2) 2 (0.5) 
 
   B.      AKI disch  No AKI Stage 1 Stage 2 
Stage 3  
no RRT 
Stage 3   
RRT 
AKI max Frequency  - n (%)      
Stage 1   50% 143 (49.1) 127 (88.8) 13 (9.1) 2 (1.4) 1 (0.7)  
Stage 2 85 (29.2) 70 (82.3) 13 (15.3) 2 (2.4)   
Stage 3  no RRT 17 (5.8) 15 (88.2) 2 (11.8)    
Stage 3 RRT 46 (15.8) 35 (76.1) 5 (10.9) 3 (6.5) 1 (2.2) 2 (4.4) 
 291 247 (84.9) 33 (11.3) 7 (2.4) 2 (0.7) 2 (0.7) 
 
   C.      AKI disch  No AKI Stage 1 Stage 2 
Stage 3  
no RRT 
Stage 3   
RRT 
AKI max Frequency  - n (%)      
Stage 1   50% 72 (25.2) 62 (86.1) 9 (12.5) 1 (1.4)   
Stage 2 45 (15.7) 34 (75.6) 7 (15.6) 4 (8.9)   
Stage 3  no RRT 58 (20.3) 31 (53.4) 12 (20.7) 13 (22.4) 1 (1.7) 1 (1.7) 
Stage 3 RRT 83 (29) 47 (56.6) 15 (18.1) 9 (10.8) 1 (1.2) 11 (13.3) 
 258 174 (67.4) 43 (16.7) 27 (10.5) 2 (0.8) 12 (4.7) 
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Table 4: baseline characteristics and general outcome of surviving AKI patients with true (available) and imputed (unavailable) 
baseline (p1 for comparison of patients with available versus unavailable baseline; p2 for comparison of no CKD patients with 
available baseline versus patients with unavailable baseline). Abbreviations: Screat = serum creatinine, eGFR = estimated 
GFR, CKD = chronic kidney disease, HD = hemodynamic support, MV = mechanical ventilation 
 
 Available baseline 
n=577 
Available baseline  
no CKD 
n= 411 
Unavailable baseline 
n=258 p1  p2  
Demographics       
Age (y)  
median (IQR) 
67.9 (58.1-75.6) 65.1 (55.7-73.9) 66 (55.5-76.5) 0.56 0.25 
Male gender - n (%) 347(60.1) 260 (63.3) 157 (60.9) 0.84 0.53 
Comorbidity      
Diabetes - n (%) 134 (23.2) 86 (20.9) 38 (14.7) 0.004 0.042 
Malignancy - n (%) 183 (31.7) 145 (35.3) 28 (10.9) <0.0001 <0.0001 
Baseline Screat mg/dL  
(median IQR)  
0.88 (0.67-1.16) 0.76 (0.58-0.91) 0.97 (0.79-1.00) 0.21 <0.0001 
Calculated baseline mg/dL 
(median IQR) 
p value for difference true-calc 
0.97 (0.78-1.00) 
0.66 
0.97 (0.79-1.00) 
<0.0001 
0.97 (0.79-1.00) 0.53 0.40 
Acute illness      
Emergency admission - n (%) 281 (48.7) 215 (52.3) 258 (100) <0.0001 <0.0001 
Surgical admission  - n (%) 495 (85.8) 350 (85.2) 189 (73.3) <0.0001 0.0002 
Sepsis on admission  - n (%) 200 (34.7) 160 (38.9) 137 (53.1) <0.0001 0.0003 
Apache II score 
(median IQR) 
26 (20-35) 27 (18-35) 37 (32-40) <0.0001 <0.0001 
Max lactate d1 mmol/L  
(median IQR)           (n=577) 
2.2 (1.6-3.3) 2.3 (1.7-3.6) 2.3 (1.4-3.7) 0.91 0.45 
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Need for HD support 522 (90.5) 365 (88.8 217 (84.1) 0.0094 0.08 
Need for MV 539 (93.4) 386 (93.9) 238 (92.2) 0.54 0.40 
Characteristics AKI      
Adm Screat mg/dL 
Median (IQR) 
1.31 (0.93-1.86) 1.18 (0.84-1.57) 1.76 (1.27-2.89) <0.0001 <0.0001 
AKI on admission 
n (% of all AKI) 
285 (49.4) 235 (57.2) 193 (74.9) <0.0001 <0.0001 
Early AKI (within 48h)         
n (% of all AKI) 
461 (79.9) 343 (83.5) 224 (86.8) 0.014 0.23 
AKI max    <0.0001 <0.0001 
Stage 1 50% 300 (52) 231 (56.2) 72 (27.9)   
Stage 2 124 (21.5) 93 (22.6) 45 (17.4)   
Stage 3 55 (9.5) 41 (10) 58 (22.5)   
Stage 3 RRT 98 (17) 46 (11.2) 83 (32.2)   
Outcome      
ICU stay 7 (4-15) 7 (4-15) 11 (5-23) <0.0001 <0.0001 
Hospital stay 27 (17-48) 28 (17-48) 35.5 (19-59) 0.0019 0.0029 
 
 
 
 
 
